Ultragenyx Pharmaceutical Inc. - Common Stock, par value $0.001 per share (RARE)

Historical Holders from Q1 2014 to Q1 2025

Symbol
RARE on Nasdaq
CUSIP
90400D108
Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
91.4M
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
87.5M
Holdings value
$3.68B
% of all portfolios
0.007%
Grand Portfolio weight change
+0%
Number of holders
312
Number of buys
146
Number of sells
-149
Average Value change %
+0%
Average buys %
+0.002%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Ultragenyx Pharmaceutical Inc. - Common Stock, par value $0.001 per share (RARE)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
SANDS CAPITAL MANAGEMENT, LLC 4.7% $165M 4.3M SANDS CAPITAL MANAGEMENT, LLC Dec 31, 2024
WELLINGTON MANAGEMENT GROUP LLP 2.7% $94.2M 2.46M Wellington Management Group LLP Dec 31, 2024

Institutional Holders of Ultragenyx Pharmaceutical Inc. - Common Stock, par value $0.001 per share (RARE)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q1 699K $25.3M +$14.5M $36.21 22
2024 Q4 87.5M $3.68B +$41.5M $42.07 312
2024 Q3 86M $4.77B -$111M $55.55 302
2024 Q2 88.2M $3.62B +$371M $41.10 271
2024 Q1 79.1M $3.69B -$57.7M $46.69 271
2023 Q4 80.4M $3.84B +$495M $47.82 232
2023 Q3 70M $2.5B +$11.1M $35.65 217
2023 Q2 68.8M $3.17B +$15.1M $46.13 234
2023 Q1 68.6M $2.75B +$26.1M $40.10 223
2022 Q4 67.9M $3.15B +$17.2M $46.33 219
2022 Q3 61.6M $2.55B -$145M $41.41 212
2022 Q2 62.1M $3.7B +$18.6M $59.66 202
2022 Q1 61.8M $4.48B -$41.8M $72.62 218
2021 Q4 67.3M $5.66B +$82M $84.09 215
2021 Q3 66.6M $6.01B +$102M $90.19 213
2021 Q2 65.4M $6.23B -$249M $95.35 232
2021 Q1 67.8M $7.73B +$50M $113.86 249
2020 Q4 67.5M $9.35B +$639M $138.43 244
2020 Q3 63.1M $5.19B -$1.95M $82.19 195
2020 Q2 63.1M $4.94B +$248M $78.22 182
2020 Q1 60.1M $2.67B +$85.6M $44.43 162
2019 Q4 55.2M $2.36B -$33.6M $42.71 160
2019 Q3 55.7M $2.38B -$47.5M $42.78 158
2019 Q2 58.7M $3.73B +$71.7M $63.50 161
2019 Q1 58M $4.02B +$543M $69.36 168
2018 Q4 50.5M $2.2B -$8.89M $43.48 154
2018 Q3 49.8M $3.8B +$72.5M $76.34 170
2018 Q2 48.8M $3.75B +$80.2M $76.87 150
2018 Q1 48.9M $2.49B +$367M $50.99 158
2017 Q4 43.2M $2B +$107M $46.38 154
2017 Q3 40.6M $2.16B -$37M $53.26 146
2017 Q2 41M $2.54B +$29.5M $62.11 150
2017 Q1 40.5M $2.74B +$147M $67.78 157
2016 Q4 41.2M $2.9B +$149M $70.31 168
2016 Q3 39.5M $2.8B +$185M $70.94 164
2016 Q2 36.4M $1.78B -$45.3M $48.91 152
2016 Q1 36.5M $2.31B +$79.8M $63.31 153
2015 Q4 35.6M $3.99B +$41.3M $112.18 164
2015 Q3 34.9M $3.36B +$212M $96.31 154
2015 Q2 32.2M $3.3B +$99.9M $102.39 147
2015 Q1 31.6M $1.96B +$230M $62.09 124
2014 Q4 27.9M $1.23B +$58.8M $43.88 99
2014 Q3 26.4M $1.5B +$358M $56.60 98
2014 Q2 15.6M $690M +$13.8M $44.89 80
2014 Q1 15.3M $730M +$730M $48.89 76